Radiation Wounds
We have had good success with the following diagnoses:
Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):871-8.
The efficacy of hyperbaric oxygen therapy in the treatment
of radiation-induced late side effects.
Bui QC, Lieber M, Withers HR, Corson K, van Rijnsoever M, Elsaleh H.
Department of Radiation Oncology, David Geffen School of Medicine at UCLA, 200
Medical Plaza B265, Los Angeles, CA 90095-6951, USA.
PURPOSE: We investigated the efficacy of hyperbaric oxygen therapy (HBOT) in the
management of patients with radiation-induced late side effects, the majority of
whom had failed previous interventions. METHODS AND MATERIALS: Of 105 eligible
subjects, 30 had either died or were not contactable, leaving 75 who qualified
for inclusion in this retrospective study. Patients answered a questionnaire
documenting symptom severity before and after treatment (using Radiation Therapy
Oncology Group criteria), duration of improvement, relapse incidence, and HBOT-related
complications. RESULTS: The rate of participation was 60% (45/75). Improvement
of principal presenting symptoms after HBOT was noted in 75% of head-and-neck,
100% of pelvic, and 57% of "other" subjects (median duration of response of 62,
72, and 68 weeks, respectively). Bone and bladder symptoms were most likely to
benefit from HBOT (response rate, 81% and 83%, respectively). Fifty percent of
subjects with soft tissue necrosis/mucous membrane side effects improved with
HBOT. The low response rate of salivary (11%), neurologic (17%), laryngeal
(17%), and upper gastrointestinal symptoms (22%) indicates that these were more
resistant to HBOT. Relapse incidence was low (22%), and minor HBOT-related
complications occurred in 31% of patients. CONCLUSION: Hyperbaric oxygen therapy
is a safe and effective treatment modality offering durable relief in the
management of radiation-induced osteoradionecrosis either alone or as an
adjunctive treatment. Radiation soft tissue necrosis, cystitis, and proctitis
also seemed to benefit from HBOT, but the present study did not have sufficient
numbers to reliably predict long-term response.
PMID: 15465205 [PubMed - indexed for MEDLINE]